117 related articles for article (PubMed ID: 7519652)
21. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
23. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
Maier U; Simak R
Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
[TBL] [Abstract][Full Text] [Related]
24. Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Grande M; Carlström K; Lundh Rozell B; Eneroth P; Stege R; Pousette A
Prostate; 2000 Dec; 45(4):299-303. PubMed ID: 11102954
[TBL] [Abstract][Full Text] [Related]
25. Serum SCC-Ag in head and neck squamous cell carcinoma.
Palermo F; Carniato A; Fede A; Boccaletto F; Marchiori C
Int J Biol Markers; 1990; 5(3):118-20. PubMed ID: 2286775
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
[TBL] [Abstract][Full Text] [Related]
28. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
29. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
30. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy.
Fijuth J; Chauvet B; Vincent P; Félix-Faure C; Reboul F
Radiother Oncol; 1992 Apr; 23(4):236-40. PubMed ID: 1376935
[TBL] [Abstract][Full Text] [Related]
31. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 22(1):27-32. PubMed ID: 1385142
[TBL] [Abstract][Full Text] [Related]
34. Serum prostate-specific antigen determination in prostatic carcinoma.
Tizzani A; Casetta G; Piana P; Bellina M; Pecchio F; Aimo G; Adamo R
Int J Biol Markers; 1987; 2(3):184-6. PubMed ID: 2453594
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.
Schwemmer B; Schütz W; Kuntz RM; Lehmer A
Urol Res; 1985; 13(3):133-6. PubMed ID: 4024395
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
39. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
[TBL] [Abstract][Full Text] [Related]
40. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]